Skip to main content
PLOS Global Public Health logoLink to PLOS Global Public Health
. 2023 Jun 21;3(6):e0001490. doi: 10.1371/journal.pgph.0001490

Quantification of early nonpharmaceutical interventions aimed at slowing transmission of Coronavirus Disease 2019 in the Navajo Nation and surrounding states (Arizona, Colorado, New Mexico, and Utah)

Ely F Miller 1, Jacob Neumann 1,¤, Ye Chen 2, Abhishek Mallela 3,4, Yen Ting Lin 5, William S Hlavacek 4, Richard G Posner 1,*
Editor: Miguel Angel Garcia-Bereguiain6
PMCID: PMC10284412  PMID: 37342996

Abstract

During an early period of the Coronavirus Disease 2019 (COVID-19) pandemic, the Navajo Nation, much like New York City, experienced a relatively high rate of disease transmission. Yet, between January and October 2020, it experienced only a single period of growth in new COVID-19 cases, which ended when cases peaked in May 2020. The daily number of new cases slowly decayed in the summer of 2020 until late September 2020. In contrast, the surrounding states of Arizona, Colorado, New Mexico, and Utah all experienced at least two periods of growth in the same time frame, with second surges beginning in late May to early June. Here, we investigated these differences in disease transmission dynamics with the objective of quantifying the contributions of non-pharmaceutical interventions (NPIs) (e.g., behaviors that limit disease transmission). We considered a compartmental model accounting for distinct periods of NPIs to analyze the epidemic in each of the five regions. We used Bayesian inference to estimate region-specific model parameters from regional surveillance data (daily reports of new COVID-19 cases) and to quantify uncertainty in parameter estimates and model predictions. Our results suggest that NPIs in the Navajo Nation were sustained over the period of interest, whereas in the surrounding states, NPIs were relaxed, which allowed for subsequent surges in cases. Our region-specific model parameterizations allow us to quantify the impacts of NPIs on disease incidence in the regions of interest.

Introduction

An outbreak of pneumonia of unknown cause starting in Wuhan, China was recognized in late December 2019 and widely reported in early January 2020 [1,2]. The disease was later named Coronavirus Disease 2019 (COVID-19) [1]. The causative agent was identified as a novel coronavirus, later named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 rapidly spread to other countries [13], and the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic on March 11, 2020 [4]. In the United States (US), during the early months of the pandemic, two regions were severely affected as measured by cumulative number of COVID-19 cases per capita: Diné Bikéyah, more commonly known as the Navajo Nation, and New York City.

On May 18, 2020, the Navajo Nation had the highest cumulative number of COVID-19 cases per hundred thousand in the US (2,344 cases per 100,000 residents), surpassing the New York City metropolitan statistical area (MSA), which had 1,806 cases per 100,000 residents [5,6]. Remarkably, both regions significantly slowed the transmission of COVID-19 and prevented additional surges in new COVID-19 cases until late September 2020 while many other regions, including the states of Arizona, Colorado, New Mexico, and Utah, each experienced a series of two surges in cases during the same period [6].

The President of the Navajo Nation and the Governors of the surrounding states of Arizona, Colorado, New Mexico, and Utah independently issued guidance and mandates to control the spread of COVID-19. These non-pharmaceutical interventions (NPIs) enforced or encouraged an array of behaviors that putatively protect susceptible individuals from SARS-CoV-2 infection, such as curtailing of travel, reduction in face-to-face interaction, face mask-wearing, working from home, etc. Although the governmental actions across the five regions were similar, there were notable differences, particularly in the duration of mandates, as we will discuss later. The disease transmission dynamics in the five regions were also different. In the Navajo Nation, the number of new cases detected daily rose sharply in late March to early April, peaked in May, and then steadily declined until late September 2020 [5]. In contrast, in each of the surrounding states, there were at least two periods of growth in new cases between 01-March-2020 and 14-September-2020 [6].

The objective of this study is to quantify the effect of early non-pharmaceutical interventions (NPIs) on the transmission of COVID-19 in the Navajo Nation (NN) and surrounding states: Arizona (AZ), Colorado (CO), New Mexico (NM), and Utah (UT). Insights into why the Navajo Nation experienced only a single period of growth in new COVID-19 cases during the period of interest while neighboring regions experienced two distinct phases of increasing case counts could point to strategies for controlling transmission of diseases similar to COVID-19 in the future. A possible explanation for the difference between the Navajo Nation (with one phase of growth in disease incidence) and the surrounding states (each with at least two phases of growth in disease incidence) is that NPIs were more effective and/or more sustained in the Navajo Nation. To evaluate this hypothesis, for each of the five regions of interest, we sought to use region-specific daily case reporting data to infer parameters of a compartmental model for COVID-19 transmission that accounts for subpopulations of susceptible individuals protected or not from SARS-CoV-2 infection by NPIs. The model structure allows for multiple phases, or periods, of NPIs. Each phase is associated with three parameters: an onset time, a sum of rate constants that defines a timescale for transition to a setpoint level of adoption of disease-avoiding behaviors, and the setpoint (the fraction of the regional population adopting disease-avoiding behaviors). We have previously shown that this model is able to reproduce the dynamics of regional COVID-19 epidemics in the 15 most populous metropolitan areas [7], including 2020 in 280 of 384 MSAs in the US [8], and in all 50 states [9].

Various studies [1014] have evaluated the effects of NPIs in different regions of the world. The general conclusion is that NPIs limit COVID-19 transmission. Here we compared NPIs that were independently mandated in five regions of interest. Among these regions, the NN had a temporal profile of disease incidence that was qualitatively distinct. Here we investigate the possibility that this difference arose from NPI-related differences.

Methods

Study design, populations and setting

In a cross-sectional study, we used regional daily COVID-19 case data collected from January 21, 2020, to September 14, 2020, a compartmental model (Fig 1), and Bayesian inference to quantify time-varying NPI effectiveness for five different populations, those of the Navajo Nation and the four surrounding states (Arizona, Colorado, New Mexico, and Utah). In our model, NPI effectiveness relates to the fraction of a population partially protected against infection and less prone to transmit disease because of adherence to NPIs. This fraction is given by a step function Pτ(t) in the model.

Fig 1. An illustration of the mechanistic compartmental model used to analyze COVID-19 data (7).

Fig 1

The model captures various subpopulations, as indicated in the legend. Transitions between subpopulations marked by M, P and Q subscripts represent adoption and relaxation of disease-avoiding behaviors. The model accounts for susceptible persons (S), exposed persons not experiencing symptoms while incubating virus (E), asymptomatic persons in the immune clearance phase of infection who never develop symptoms (A), infected persons with mild symptoms (I), infected persons with severe illness (H), deceased persons (D), and recovered persons (R). The incubation period is divided into five stages. Red (subscript M) indicates persons in the mixing population, blue (subscript P) indicates persons in the protected population, green (subscript Q) indicates persons in the quarantined or self-isolated population, and white indicates persons who are recovered, hospitalized, or deceased.

The entire communities of the Navajo Nation and the four surrounding states were considered in this study. We considered disease prevalence in these five regions. Disease prevalence could be affected by age, household size, income/socioeconomic factors, population density, and occupational exposure. These factors were not considered in the study.

Comparison of NPI effectiveness in the Navajo Nation to that of the surrounding states was motivated by several considerations. The Navajo Nation experienced the highest per capita COVID-19 incidence in the US early during the pandemic [5]. Moreover, the time profile of disease incidence was qualitatively distinct from that of each of the four surrounding states, and the NPI mandates for the Navajo Nation were different from those of the surrounding states. Mandates were different partly because they were issued by the president of the Navajo Nation independently of state governors. Even if the mandates had been identical, the effectiveness of NPIs can vary depending on social structures. The Navajo Nation has unique social structures compared to the surrounding states. The Navajo Nation has one of the lowest population densities within the US, approximately seven persons per square mile. Persons of the Navajo Nation primarily live in clusters, where many individuals share the same household. Thus, despite low population density over the entire geographical area, household density can be quite high [15].

Data collection and sources

We used public data extracted from newspapers and online resources. The COVID-19 surveillance data used to parameterize the model for the Navajo Nation were obtained from the Navajo Times COVID-19 webpage [5]. The Navajo Times provided daily reports of new confirmed COVID-19 cases over the period of interest. The reported source of this information was the Navajo Nation Department of Health (NNDOH) [16]. The COVID-19 surveillance data used to parameterize the models for Arizona, Colorado, New Mexico, and Utah were obtained from a GitHub repository maintained by The New York Times newspaper [17]. This GitHub repository collects new case reports from local health agencies in the United States. For each of the four states, we aggregated county-level case counts to obtain state-level case counts. In all regions of interest, positive cases were assessed according to CDC guidelines [18].

Regional NPIs were set by the president of the NN and the governors of AZ, CO, NM, and UT. Information about NPI mandates in the four states were obtained from the John Hopkins Coronavirus Resource Center [19]. This NPI resource webpage collects state-wide NPI mandates issued by each US state’s governor and plots when they were issued against daily new cases to visualize the effect of NPIs on trends in new COVID-19 cases. The John Hopkins Coronavirus Resource Center collects policy data from various state-specific websites such as state and governor websites and from the National Governors Association. It should be noted that information in this resource characterizes state-level mandates only; information about county-level mandates is less readily available and was not considered in this study. Information about NPI mandates in the Navajo Nation was obtained from the NNDOH public website [16]. For our study we considered 4 types of NPIs: weekend lockdown, closure of nonessential businesses, mask mandates, and limitations on mass gatherings.

Study bias

Information bias is a concern because the number of regional cases depends on the region-specific surveillance effort. To help account for information bias, we assumed that the detected fraction of cases is region-specific and constant over the time frame of interest. For each region, we estimated a parameter in our model fD, the detected fraction of cases.

Model and simulations

The model we considered in this study is that of Lin et al. [7]. It is a compartmental model that divides a regional population of interest into susceptible (S), exposed (E), infectious (I), and removed (R) compartments (Fig 1). Exposed persons transition through a series of five stages, introduced to capture the distribution of incubation times observed for COVID-19 [20]. The model also accounts for quarantine, self-isolation because of symptom awareness, hospitalization, and death. Importantly, persons are allowed to transition between two modes of behavior, in which they are either protected (imperfectly) from infection (because of adoption of disease-avoiding behaviors) or are mixing freely (i.e., taking no special precautions to prevent infection). The model tracks 25 compartments. Each compartment corresponds to an ordinary differential equation (ODE). There is an auxiliary 1-parameter measurement model, which relates the variables of the compartmental model to reported new cases through surveillance testing [7]. The equations of the mechanistic compartmental model and the measurement model can be found in Appendix 1 of Lin et al. [7].

The model accounts for an initial phase of NPIs beginning at time t = σ, where σ is fixed to the date the region of interest accumulated at least 200 COVID-19 cases. The model can be extended to account for n additional periods. Thus, the total number of NPI periods considered in a regional model is given by n + 1 [7]. The start of a new NPI phase is accompanied by step changes in the values of the three NPI parameters. In the models for the Navajo Nation (NN), Arizona (AZ), Colorado (CO), New Mexico (NM), and Utah (UT), we considered three possible settings for n (the number of additional NPI periods beyond the initial period): n = 0 (only one NPI period over the entire period of interest), n = 1 (two NPI periods), and n = 2 (three NPI periods). The setting for n was determined as described below.

To determine the structure of the compartmental model for each region of interest (i.e., the number of distinct NPI phases), we used a heuristic model-selection method. In this approach, we calculated the value of the Akaike information criterion corrected for small sample size (AICc) for n and n + 1 versions of the model, where n = 0, 1. We also calculated the value of the Bayesian information criterion (BIC) for the same two versions of each model. ΔAICc is defined as the change in AICc between n and n + 1 versions of the models: ΔAICc = AICcnAICcn+1. ΔBIC is defined similarly: ΔBIC = BICnBICn+1. We adopted n + 1 over n when both of the following conditions held true: ΔAICc > 10 and ΔBIC > 10. The method of model selection described above was used to decide between the use of n = 0 and n = 1, and between the use of n = 1 and n = 2 [7,21].

In the case of only an initial NPI period (n = 0), the compartmental model and auxiliary measurement model have 20 parameters combined. Five of the parameters (t0, p0, λ0, β, and fD) are considered adjustable; these parameters are all region dependent. The other 15 parameters are taken to have fixed values. The 15 fixed parameters are S0, σ, I0, mb, ρE, ρA, kL, kQ, jQ, fA, fH, fR, cA, cI, and cH. The parameter S0 represents the total population of the region of interest, as determined by census data [22], which we took to be fixed. I0 refers to the starting number of infected individuals. We used I0 = 1. ρE and ρA refer to the relative infectiousness of exposed persons and asymptomatic persons, respectively, compared to symptomatic persons [23,24]. Infected persons are taken to enter quarantine with rate constant kQ and persons with symptoms and mild disease are taken to self-isolate with rate constant jQ. Persons in the protected subpopulation (i.e., persons adopting disease-avoiding behaviors) are taken to be less likely to acquire or transmit disease by a factor mb. In the model, the incubation period is divided into 5 stages. Movement from one stage to the next occurs with rate constant kL [20]. The fraction of exposed persons who never become symptomatic is represented by fA. The fraction of symptomatic persons who progress to severe disease (and hospitalization or isolation at home) is represented by fH [25]. The fraction of persons with severe disease who recover is represented by fR. Persons with asymptomatic disease leave the immune clearance stage of infection and recover with rate constant cA [26]. Persons with mild symptomatic disease recover with rate constant cI [27]. Persons with severe disease recover with rate constant cH [28]. The five adjustable parameters are t0, p0, λ0, β, and fD. The parameter t0 refers to the start time of local sustained COVID-19 transmission; p0 is the initial non-zero value of Pτ(t), the stationary fraction of the local population that is practicing disease-avoiding behaviors; λ0 is the initial non-zero value of Λτ(t), a sum of rate constants that establishes a time scale for the establishment of the quasi-stationary state of NPIs; β is the disease transmission rate constant (or contact rate parameter) in the absence of NPIs; and fD is the fraction of new infections detected in surveillance. The parameter fD characterizes the effectiveness of surveillance and relates new cases to new infections. In the model, Pτ (t) and Λτ(t) are taken to be step functions. Each of these functions has a value of 0 until t = σ and thereafter changes value at a set of n times (if n > 0), denoted τ = {τ1 > σ, …, τn > τn-1}. The value of n starts at 0 and is incremented through model selection as described above. There is one additional adjustable parameter, r, the dispersion parameter of a negative binomial distribution NB(p, r) used to characterize noise in case detection [7]. The value of r is inferred jointly with the five adjustable model parameters.

In the case of one additional NPI period beyond the initial period (n = 1), three more adjustable parameters are used, which are denoted τ1, p1, and λ1. The latter two parameters determine the new values of Pτ(t), and Λτ(t) at time t = τ1, the start time of the second phase of NPIs. In general, three more adjustable parameters are added to the model each time n is incremented. The equations of the compartmental model and of the auxiliary model can be found in Appendix 1 of Lin et al. [7].

Simulations were performed using ODE solvers available within the SUNDIALS software package [29].

Data analysis

Bayesian inference was enabled by Markov chain Monte Carlo (MCMC) sampling, which yielded posterior samples for NPI parameters of region-specific compartmental mathematical models. Inferences were based on COVID-19 daily confirmed case count data available for the period starting on 21-January-2020 and ending on 14-September-2020. Inferences were conditioned on one to three periods of NPIs, uniform proper priors, a negative binomial model for surveillance noise, and estimates of selected parameters taken to have the same values across all regions of interest [7]. Following Lin et al. [7], we used model selection to determine the most parsimonious number of NPI periods. A model structure and parameterization were thus found for each region of interest. Each parameterization allows the model with selected structure to explain the corresponding regional epidemic curve.

We quantified uncertainty in daily case reports through resampling of the parameter posterior to generate a posterior predictive distribution for daily number of new cases detected [7].

We used an adaptive MCMC sampling algorithm described earlier [30] and implemented in the PyBioNetFit software package [31]. PyBioNetFit job setup files for the inferences performed in this study, including data files, are available online (https://github.com/lanl/PyBNF/tree/master/examples/Miller2022NavajoNation).

Ethical considerations

This research is not considered human subjects research because we played no role in the collection of the data, the data does not include any identifying information, and the data were obtained from public sources.

Results

The model we used to analyze data from the NN and surrounding states is illustrated in Fig 1. The model accounts for movement of persons between different states of protection against SARS-CoV-2 infection because of disease-avoiding behaviors. In the model, persons are allowed to be in three states of protection: a state in which an uninfected person is protected imperfectly against infection because of disease-avoiding behaviors, a state in which an uninfected person is more exposed to infection because they do not take any special precautions to avoid infection, and a state in which an infected person is quarantined or in self-isolation. In the model, an initial NPI period (n = 0) begins as soon as the number of cumulative cases reaches or exceeds 200. A new NPI period is introduced through the model-selection procedure described in Methods. When a new NPI period is introduced, n is incremented and NPI parameters change.

Figs 2 and 3 show 95% credible intervals of posterior predictive distributions for daily case detection for the NN and the four surrounding states. Posterior predictive distributions were found by drawing from parameter posterior samples generated through MCMC sampling, thereby propagating parametric uncertainty into prediction uncertainty. In the posterior predictive distributions, NN only has one surge in disease incidence whereas the surrounding states each have at least two surges.

Fig 2. Posterior predictive distribution for new cases detected in the Navajo Nation between 21-January-2020 and 14-September-2020.

Fig 2

The daily number of new COVID-19 cases detected in the Navajo Nation are indicated by red markers. The median percentiles of posterior samples are shown in purple. The blue curve indicates daily number of new infections and is based on MAP estimates for model parameters. The vertical black dotted line represents the time at which NPIs began in the Navajo Nation. The horizontal black dotted line indicates the duration of the initial NPI phase. It should be noted that the left and right vertical scales are different.

Fig 3. Posterior predictive distributions for new cases in the four US states surrounding the Navajo Nation between 21-January-2020, and 14-September-2020: (A) Arizona, (B) Colorado, (C) New Mexico, and (D) Utah.

Fig 3

Recorded region-specific daily new cases of COVID-19 are indicated by red markers in each panel. The median parameter posterior estimates are shown in purple. The yellow bands delimited the 2.5 and 97.5 percentiles; the entire shaded region indicates the 95% credible interval. In each panel, the blue curve indicates daily number of new infections and is based on MAP estimates for region-specific model parameters. The start times of NPI phases are indicated by vertical dotted lines. The initial NPI phase begins when t = σ, the second NPI phase begins when t = τ1, and the third NPI phase begins when t = τ2. The horizontal black dotted lines indicate durations of NPI phases. It should be noted that the size of the first surge in Arizona, occurring in March and April 2020, is dwarfed by the size of the second surge. It should be noted that the left and right vertical scales of each panel are different.

Figs 2 and 3 show curves for the daily number of new symptomatic infections (vs. cases) based on maximum a posteriori (MAP) estimates for parameters (which are equivalent to maximum likelihood estimates because of the use of uniform proper priors). In our calculations, the number of detected cases over a 1-d period is taken to be a fraction fD of the number of new symptomatic infections generated during that same period. The value of fD is region-specific. The MAP estimate for fD is 0.2 for the Navajo Nation, 0.15 for Arizona, 0.35 for Colorado, 0.04 for New Mexico, and 0.07 for Utah.

Figs 2 and 3 indicate when distinct NPI periods were determined to have begun. Table 1 summarizes results of the model-selection procedure used to decide between 1 or 2 or more NPI phases for each region of interest. The Navajo Nation was the only region of interest to have ΔAICc and ΔBIC values indicating only one NPI phase.

Table 1. Results from our model-selection procedure used to select the number of NPI periods in each region.

Region ΔAICc ΔBIC
Navajo Nation -6.4 -15.7
Arizona 76.2 66.7
Colorado 108.3 99.1
New Mexico 56.6 47.4
Utah 98.1 89.0

We calculated the value of the Akaike information criterion corrected for small sample size (AICc) for n = 0 and n = 1 versions of the model, as well as and value of the Bayesian information criterion (BIC) for the same two versions of each model. We defined ΔAICc = AICcn = 0AICcn = 1 and BIC = BICn = 0BICn = 1. We adopted n = 1 over n = 0 when ΔAICc > 10 and ΔBIC > 10 (i.e., we reject the hypothesis that n = 0 when both ΔAICc and ΔBIC are greater than 10). Accordingly, n = 0 is indicated only for the Navajo Nation and n > 0 is indicated for all four surrounding states.

Fig 4 shows the marginal posteriors of the setpoint parameters {p0,…,pn} for each region, which were generated by MCMC sampling. Recall that each of these parameters determines the quasi-stationary population fraction adopting disease-avoiding behaviors and that there is a distinct setpoint for each distinct NPI phase (e.g., p0, p1, and p2 for a region with three distinct NPI phases). For the Navajo Nation, we inferred only a single NPI phase over the period of interest. This phase is characterized by a NN-specific value for the setpoint parameter p0. The marginal posterior for p0 for the NN is shown in Fig 4A. In surrounding states, we inferred changes in adherence to disease-avoiding behaviors, i.e., different setpoints over time. The marginal posteriors for the state-specific setpoint parameters are shown in Fig 4B–4E.

Fig 4. Marginal posteriors for parameters of the setpoint function Pτ(t) (e.g., p0) for (A) Navajo Nation, (B) Arizona, (C) Colorado, (D) New Mexico, and (E) Utah for the time period January 21, 2020, to September 14, 2020.

Fig 4

Recall that Pτ(t) denotes the fraction of the population practicing disease-avoiding behaviors at time t. The value of Pτ(t), a step function, is determined by one or more setpoint parameters, denoted p0, p1, etc. The Navajo Nation setpoint function parameter has the following maximum a posteriori (MAP) value: p0 = 0.35. The Arizona setpoint function parameters have the following MAP values: p0 = 0.60 and p1 = 0.5. The Colorado setpoint function parameters have the following MAP values: p0 = 0.47, p1 = 0.27, and p2 = 0.11. The New Mexico setpoint function parameters have the following MAP values: p0 = 0.34, p1 = 0.19, and p2 = 0.05. The Utah setpoint function parameters have the following MAP values: p0 = 0.43, p1 = 0.35, and p2 = 0.21 For each region of interest, the NPI switch times, τ = {τ1, …,τn}, are indicated in Fig 3.

Comparison of the marginal posteriors for different NPI phases within a given state reveals a relaxation in disease-avoiding behaviors in each state. Fig 5 shows MAP estimates for NPI setpoint parameters (e.g., p0) for each region of interest over time. A higher setpoint indicates a higher prevalence of disease-avoiding behaviors. For the period of interest, we found that all regions experienced a decrease in their setpoint parameter values after an initial NPI phase except the Navajo Nation. Although Arizona, Colorado, and Utah initially had a higher setpoint than the Navajo Nation, the Navajo Nation maintained the initial setpoint for a longer period in comparison to the surrounding states.

Fig 5. Value of the NPI setpoint function Pτ(t) over time based on MAP estimates for NPI setpoint parameters {p0,…, pn} for (A) Navajo Nation (B) Arizona, (C) Colorado, (D) New Mexico, and (E) Utah.

Fig 5

The period considered is 21-January-2020 to 14-September-2020.

Fig 6 shows Navajo Nation COVID-19 case data from 21-January-2020 to 5-February-2021 and projections of daily case counts for selected NPI scenarios after 14-September-2020. Between 21-January-2020 and 14-September-2020, the Navajo Nation maintained disease-avoiding behaviors (as characterized by the setpoint parameter p0) and experienced only one surge in COVID-19 cases. However, after this period, the Navajo Nation experienced an additional surge in COVID-19 cases. The solid red curve in Fig 6 is the trajectory corresponding to the MAP estimate of p1, obtained using data collected after 14-September-2020, and the dotted curves are different hypothetical trajectories based on lower and higher values for the NPI parameter p1. We found that the Navajo Nation would have needed to maintain a value for p1 greater than 0.27 after 14-September-2020 to avoid a surge in disease transmission.

Fig 6. Model-derived projections for various scenarios in which the NPI parameter p1, which indicates the fraction of the population practicing disease-avoiding behaviors in a second NPI phase in the Navajo Nation starting 14-September-2020, was adjusted to identify the threshold required to prevent a second surge in cases.

Fig 6

The red solid line corresponds to the MAP estimate for p1, which is approximately 0.19. The blue broken line indicates the predicted trajectory for daily cases when p1 is fixed at 0.15. The orange broken line corresponds to a scenario wherein p1 is fixed at 0.22, the green broken line corresponds to a scenario wherein p1 is fixed at 0.25, the pink broken line corresponds to a scenario wherein p1 is fixed at 0.27, and the brown broken line corresponds to a scenario wherein p1 is fixed at 0.35.

Fig 7 presents a timeline of governmental mandates between 21-January-2020 and 14-September-2020 in the Navajo Nation and the four surrounding states. Four mandates are considered, which are related to face mask wearing, mass gatherings, non-essential business closures, and weekend lockdowns. As can be seen, these mandates were in effect for the longest duration in the Navajo Nation. Mandates in surrounding states were in effect for shorter durations and were imposed less consistently.

Fig 7. Timeline for mandated NPIs in the Navajo Nation and surrounding states between 01-March-2020 and 14-September-2020.

Fig 7

Each region is represented by a different color, as indicated. Only mandates issued by state governors and the president of the Navajo Nation are considered.

Discussion

In this study, we used a compartmental model to quantify the overall effect of non-pharmaceutical interventions (NPIs) on COVID-19 transmission in specific regions, namely the Navajo Nation and the four surrounding states. In our model, we do not consider multiple strains of SARS-CoV-2 because during the time period of interest (21-January-2020 to 14-September-2020) variants of concern had yet to emerge. The first variant of concern (Alpha, B.1.1.7) appeared in the United Kingdom (UK) in late September of 2020 [32] and was detected in the US in November 2020, which is beyond the time window of our study [33].

The model for a given region includes a set of NPI setpoint parameters, each of which represents the quasi-stationary fraction of the regional population that is practicing disease-avoiding behaviors for a given period. By using surveillance data (daily case counts) to infer the region-specific values of the NPI setpoint parameters, we quantified the relative overall effectiveness of NPIs across the regions of interest.

From 21-January-2020 to 14-September-2020, we found that the Navajo Nation maintained the initial NPI setpoint throughout this period (Figs 4 and 5), consistent with a single surge in COVID-19 incidence (Fig 2). In contrast, we found that the surrounding states of Arizona, Colorado, New Mexico, and Utah did not. That is, each surrounding state had two or more NPI phases, marked by different NPI setpoints and multiple surges in COVID-19 incidence. These findings are consistent with a comparison of governmental mandates across the five regions of interest (Fig 7). Sustained NPIs is unique to the Navajo Nation and suggests an explanation for why this region experienced only one surge in COVID-19 cases while other regions experienced multiple surges. A generalizable result that we obtained is that sustained adherence to NPIs can prevent surges in disease incidence whereas relaxation of NPIs can lead to surges in disease. Our results add evidence in support of the idea that the duration of NPI adherence is an important factor influencing their effectiveness [34,35].

Interestingly, we inferred that the fraction of the NN population adopting disease-avoiding behaviors upon initial implementation of NPIs was lower than that in Arizona, Colorado, and Utah and similar to that in New Mexico. These results implicate sustained NPIs (rather than effectiveness of NPIs) as the reason for the different disease transmission dynamics between the Navajo Nation (only a single surge in disease incidence) and the surrounding states (multiple surges).

Consistent with other studies reviewed by Lison et al. [10], our results suggest that NPIs, even if only partially adopted, can slow and control disease transmission if mandates are consistent and are not relaxed prematurely or to too great an extent. We determined that the Navajo Nation’s NPI setpoint parameter value between 21-January-2020 and 14-September-2020 was 0.35 but the value changed to 0.19 after 14-September-2020, preceding a second surge in disease incidence. We determined the NN minimum NPI setpoint parameter value needed to maintain control of disease transmission (i.e., to avoid a surge in disease incidence) to be 0.27 (Fig 6). In other words, the second surge in the NN could have been prevented if 27% of the population had maintained disease-avoiding behaviors after 14-September-2020.

We inferred two other notable differences between the regions of interest beyond differences in adoption of effective NPIs. First, surveillance efforts may have had different levels of effectiveness. Our MAP estimates for fD, the fraction of new infections detected, ranged from a low of 0.04 for New Mexico to a high of 0.35 for Colorado. Colorado, New Mexico, and Utah had similar numbers of cases per 100,000 residents but the inferred differences in surveillance effectiveness suggest that COVID-19 impacts were significantly greater in New Mexico and Utah than in Colorado. Second, there were differences in contagiousness across the regions of interest. Our MAP estimates for β, the contact rate parameter, ranged from just over 0.3 per day for the Navajo Nation and New Mexico to just over 0.5 per day for Arizona. Using the formula for the basic reproduction number R0 given by Mallela et al. [9], these differences in β estimates translate into the following estimated R0 values for the five regions: 3.6 for New Mexico, 3.7 for the Navajo Nation, 4.4 for Utah, 4.6 for Colorado, and 5.9 for Arizona. Thus, the relatively high adoption of effective NPIs in Arizona was offset by relatively high transmission of COVID-19. Our analysis does not provide insight into why contagiousness varied across the regions of interest.

We detected changes in disease-avoiding behaviors over time using a model selection procedure, which indicates when an NPI setpoint needs to change value for consistency with surveillance data. Our approach for detecting changes in disease-avoiding behaviors has at least two limitations. First, we cannot ascertain the relative effectiveness of individual NPIs. The reason is that our model only accounts for the overall effect of all NPIs. In the model, persons are either protected by NPIs or not. Second, our model can only explain surges in disease incidence caused by relaxation of NPIs. The model does not account for other factors that could cause surges, such as an increased disease transmissibility associated with emergence of a viral variant of concern or loss of immunity. Variants of concern did not emerge during the period of interest [32,33]. Sterilizing immunity against SARS-CoV-2 infections wanes but reinfection was unlikely to contribute to disease incidence during the period of interest [36].

In summary, our analysis suggests that once NPIs have brought an outbreak under control, relaxation of the NPIs can be implemented but relaxation should be measured to avoid a new surge in disease incidence. A relatively low level of disease incidence is not an indicator that NPIs can be safely relaxed. In future pandemics a model accounting for NPIs could perhaps be used to guide relaxation of NPIs [37].

Data Availability

All data available on GITHUB: https://github.com/lanl/PyBNF/tree/master/examples/Miller2022NavajoNation.

Funding Statement

YC, WSH, EFM, JN, and RGP acknowledge support from the National Institute of General Medical Sciences of the National Institutes of Health (grant R01GM111510). AM acknowledges support from the 2020 National Science Foundation Mathematical Sciences Graduate Internship Program and the Center for Nonlinear Studies at Los Alamos National Laboratory. WSH and YTL acknowledge support from the Laboratory Directed Research and Development Program at Los Alamos National Laboratory (project 20220268ER). We acknowledge use of the Monsoon computer cluster at Northern Arizona University, which is funded by Arizona’s Technology and Research Initiative Fund to YC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020. doi: 10.1038/s41564-020-0695-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. New England Journal of Medicine. 2020;382(10):929–36. doi: 10.1056/NEJMoa2001191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.The Covid Tracking Project [Internet]. https://covidtracking.com/.
  • 4.Cucinotta D, Vanelli M; CDV. Who declares COVID-19 a pandemic [Internet]. Acta bio-medica: Atenei Parmensis. U.S. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/32191675/. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.COVID-19 Across the Navajo Nation [internet]. https://navajotimes.com/coronavirus-updates/covid-19-across-the-navajo-nation/.
  • 6.Coronavirus in the U.S.: Latest map and case count—The New York Times [Internet]. https://www.nytimes.com/interactive/2021/us/covid-cases.html.
  • 7.Lin YT, Neumann J, Miller EF, Posner RG, Mallela A, Safta C, et al. Daily forecasting of regional epidemics of coronavirus disease with Bayesian uncertainty quantification, United States. Emerging Infectious Diseases. 2021;27(3):767–78. doi: 10.3201/eid2703.203364 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Mallela A, Lin YT, Hlavacek WS. Differential contagiousness of respiratory disease across the United States [Internet]. medRxiv. Cold Spring Harbor Laboratory Press; 2022. https://www.medrxiv.org/content/10.1101/2022.09.15.22279948v1. [DOI] [PubMed] [Google Scholar]
  • 9.Mallela A, Neumann J, Miller EF, Chen Y, Posner RG, Lin YT, et al. Bayesian inference of state-level COVID-19 basic reproduction numbers across the United States. Viruses. 2022;14(1):157. doi: 10.3390/v14010157 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lison A, Banholzer N, Sharma M, Mindermann S, Unwin HJ, Mishra S, et al. Effectiveness assessment of non-pharmaceutical interventions: Lessons learned from the covid-19 pandemic. The Lancet Public Health, 2023; 8(4). doi: 10.1016/S2468-2667(23)00046-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Teslya A, Pham TM, Godijk NG, Kretzschmar ME, Bootsma MC, Rozhnova G. Impact of self-imposed prevention measures and short-term government-imposed social distancing on mitigating and delaying a COVID-19 epidemic: A modelling study. PLOS Medicine, 2020;17(7). doi: 10.1371/journal.pmed.1003166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gatto M, Bertuzzo E, Mari L, Miccoli S, Carraro L., Casagrandi R., et al. Spread and dynamics of the covid-19 epidemic in Italy: Effects of emergency containment measures. Proceedings of the National Academy of Sciences, 2020;117(19), 10484–10491. doi: 10.1073/pnas.2004978117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Liu Y, Morgenstern C, Kelly J, Lowe R, Jit M. The impact of non-pharmaceutical interventions on SARS-COV-2 transmission across 130 countries and Territories. BMC Medicine, 19(1). doi: 10.1186/s12916-020-01872-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Jefferson T, Dooley L, Ferroni E, Al-Ansary LA, van Driel ML, Bawazeer GA, et al. ‘Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database of Systematic Reviews, 2023(4). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kovich H. Rural matters—coronavirus and the Navajo Nation. New England Journal of Medicine, 2021, 383(2), 105–107. [DOI] [PubMed] [Google Scholar]
  • 16.Dikos Ntsaaígíí-19 (COVID-19) [Internet]. Navajo Nation Department of Health. https://www.ndoh.navajo-nsn.gov/COVID-19.
  • 17.New York Times. COVID-19-data: An ongoing repository of data on coronavirus cases and deaths in the U.S. [Internet]. GitHub. https://github.com/nytimes/covid-19-data.
  • 18.CDC. Data & Surveillance. Centers for Disease Control and Prevention (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/index.html.
  • 19.Impact of opening and closing decisions in the U.S.- Johns Hopkins [Internet]. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/data/state-timeline.
  • 20.Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of Coronavirus Disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Annals of Internal Medicine. 2020;172(9):577–82. doi: 10.7326/M20-0504 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Burnham KP, Anderson DR. Multimodel inference. Sociological Methods & Research. 2004;33(2):261–304. [Google Scholar]
  • 22.U.S. Census Bureau, 2020. https://www.census.gov/en.html.
  • 23.Van Vinh Chau N, Lam VT, Dung NT, Yen LM, Minh NNQ, Hung LM, et al. The natural history and transmission potential of asymptomatic severe acute respiratory syndrome coronavirus 2 infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. U.S. National Library of Medicine; 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-COV-2 infections, and transmission in a skilled nursing facility. New England Journal of Medicine. 2020;382(22):2081–90. doi: 10.1056/NEJMoa2008457 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with covid-19 in the New York City area. JAMA. 2020;323(20):2052. doi: 10.1001/jama.2020.6775 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki S-ichiro, Ishihara T, et al. Natural history of asymptomatic SARS-COV-2 infection. New England Journal of Medicine. 2020;383(9):885–6. doi: 10.1056/NEJMc2013020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Perez-Saez J, Lauer SA, Kaiser L, Regard S, Delaporte E, Guessous I, et al. Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland. The Lancet Infectious Diseases. 2021;21(4). doi: 10.1016/S1473-3099(20)30584-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with Covid-2019. Nature. 2020;581(7809):465–9. doi: 10.1038/s41586-020-2196-x [DOI] [PubMed] [Google Scholar]
  • 29.Gardner DJ, and Reynolds DR, Woodward, CS, Cody J. (2022). Enabling new flexibility in the SUNDIALS suite of nonlinear and differential/algebraic equation solvers. GitHub. https://github.com/LLNL/sundials#:~:text=SUNDIALS%20is%20a%20family%20of%20software%20packages%20providing,can%20easily%20be%20incorporated%20into%20existing%20simulation%20codes.
  • 30.Andrieu C, Thoms J. A tutorial on adaptive MCMC. Statistics and Computing. 2008;18(4):343–73. [Google Scholar]
  • 31.Neumann J, Lin YT, Mallela A, Miller EF, Colvin J, Duprat AT, et al. Implementation of a practical Markov chain Monte Carlo sampling algorithm in PyBioNetFit. Bioinformatics. 2022;38(6):1770–2. doi: 10.1093/bioinformatics/btac004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Walker AS, Vihta KD, Gethings O, Pritchard E, Jones J., House T, et al. Tracking the emergence of SARS-COV-2 alpha variant in the United Kingdom. New England Journal of Medicine, 385(27), 2582–2585. doi: 10.1056/NEJMc2103227 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Washington NL, Gangvarapu K, et al. (2021). "Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States". MedRxiv: The Preprint Server for Health Sciences. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Lai S, Ruktanonchai NW, Zhou L, Prosper O, Luo W, Floyd JR, et al. Effect of non-pharmaceutical interventions to contain COVID-19 in China. Nature, 2020;585(7825), 410–413. doi: 10.1038/s41586-020-2293-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Davies NG, Kucharski AJ, Eggo RM, Gimma A, Edmunds WJ, Jombart T, et al. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: A modelling study. The Lancet Public Health, 2020;5(7). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Deng L, Li P, Zhang X, Jiang Q, Turner D, Zhou C, et al. Risk of SARS-COV-2 reinfection: A systematic review and meta-analysis. Scientific Reports, 2022;12(1). doi: 10.1038/s41598-022-24220-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Menegale F, Manica M, Zardini A, Guzzetta G, Marziano V, d’Andrea V, et al. Evaluation of waning of SARS-COV-2 vaccine–induced immunity. JAMA Network Open, 2023; 6(5). doi: 10.1001/jamanetworkopen.2023.10650 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLOS Glob Public Health. doi: 10.1371/journal.pgph.0001490.r001

Decision Letter 0

Miguel Angel Garcia-Bereguiain

18 Apr 2023

PGPH-D-22-02023

Quantification of early nonpharmaceutical interventions aimed at slowing transmission of Coronavirus Disease 2019 in the Navajo Nation and surrounding states (Arizona, Colorado, New Mexico, and Utah)

PLOS Global Public Health

Dear Dr. Posner,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 02 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Miguel Angel Garcia-Bereguiain, PhD

Academic Editor

PLOS Global Public Health

Journal Requirements:

1. Please amend your detailed online Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published.

a) State the initials, alongside each funding source, of each author to receive each grant. For example: "This work was supported by the National Institutes of Health (####### to AM; ###### to CJ) and the National Science Foundation (###### to AM)."

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

2. Please update your online Competing Interests statement. If you have no competing interests to declare, please state: “The authors have declared that no competing interests exist.”

3. We ask that a manuscript source file is provided at Revision. Please upload your manuscript file as a .doc, .docx, .rtf or .tex.

4. Please remove any figures embedded in your manuscript file, leaving only the individual TIFF/EPS image files. You may leave the figure captions or legends in the manuscript.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In the summary part, the IMRaD structure must be respected. Break down each part. The main objective of the study should be clearly stated. If possible, the main results in terms of quantification of the measures, which really show the measured impact of the interventions, should also be included.

I would therefore like to see the whole summary taken up again, taking into account the comments.

The introduction failed to address the general aspect of the subject. It would therefore be better to shed light on the situation of approaches that have approached it in the same way in other countries outside your study framework. As a result, your discussion has stopped at mere comments. There is really no discussion under the subheading discussion of results with those of other authors discussion.

It would be really interesting to compare your work with what other authors have done elsewhere. If not present, mention it too.

Do not mix the methods and introduction sections

Why, is it directly in the results section that the objective of the study was first stated? Is it a result? I don't think so. I would like to see it brought back to the introduction of the abstract part and the end of the introduction part of the body of the article.

Reviewer #2: Comments

Dear authors have submitted a manuscript entitled "Quantification of early nonpharmaceutical interventions aimed at slowing transmission of Coronavirus Disease 2019 in the Navajo Nation and surrounding states (Arizona, Colorado, New Mexico, and Utah)". This manuscript is the product of Bayesian inference-based modeling and reports a very interesting finding that the effectiveness of NPIs lies in the fact that they are sustained measures rather than measures per se. This is very interesting research, however, there are limitations, especially methodological ones, which should be corrected before the manuscript is accepted.

Introduction

In general, the introductory section is well written and groups the most important aspects to provide context to the research.

However, in the last paragraph, between lines 93 and 103, the objective of the research is stated, and a brief "summary" of the methodology used is added. In the context of the form of the manuscript this is not correct. Please replace the text from line 93 to 103 with the proposed overall research objective of the manuscript.

Methodology

Dear authors, the materials and methods section, while describing useful and important information for the manuscript, has important deficiencies that must be addressed before the manuscript can be accepted for publication.

Although this is a modeling-based study, it is recommended that the section be restructured according to STROBE guidelines as soon as the methodology allows, including the sections on:

Study design

Setting

Exposure

Outcome

Data sources

Model calculation and modeling process

For example, the text between line 105 and 125 should be added to the "Data sources" section.

The description of the modeling performed is quite complete and I consider that the analysis methods are correct, however, the description as with the rest of the text in the methodology section should be structured in the corresponding section "Model calculation and modeling process". Please, in cases where equations are used make sure that these are described after an end point using the corresponding function to provide greater understanding to the reader.

As mentioned above, please make sure to add or restructure the necessary information to cover the mentioned sections.

Results

Please move the research objective to the end of the Introduction section.

Likewise, move the text from lines 208 to 213 to the corresponding section in the Methods section.

For the rest, the findings proposed in the results section should be objective to avoid confusion among readers, the figures are adequate and of quality I consider that they do not require changes.

Discussion

Line 282 to 289: Initially the limitations of the study should be mentioned in the final paragraph of the discussion section. On the other hand, they claim the limitation of not being able to determine the relative efficacy of NPIs equally, please add a logical argument for this limitation.

Also, while it is true that they mention that the model does not consider other variables that could make it more accurate, this is a correct assertion. However, regarding the possible association with the emergence of new SARS-CoV-2 variants, despite not being able to perform complex statistical analyses, you could conduct a descriptive analysis of variant circulation in the Navajo Nation and surrounding cities to weigh your findings against variants that were shown to have higher transmissibility rates than the native variant such as the Omicron variant. If you do not have access to this information, please add a detailed description of your limitation in the appropriate section.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Nicolas Hamondji AMEGAN

Reviewer #2: Yes: Juan S. Izquierdo-Condoy

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0001490.r003

Decision Letter 1

Miguel Angel Garcia-Bereguiain

30 May 2023

Quantification of early nonpharmaceutical interventions aimed at slowing transmission of Coronavirus Disease 2019 in the Navajo Nation and surrounding states (Arizona, Colorado, New Mexico, and Utah)

PGPH-D-22-02023R1

Dear Dr Posner,

We are pleased to inform you that your manuscript 'Quantification of early nonpharmaceutical interventions aimed at slowing transmission of Coronavirus Disease 2019 in the Navajo Nation and surrounding states (Arizona, Colorado, New Mexico, and Utah)' has been provisionally accepted for publication in PLOS Global Public Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health.

Best regards,

Miguel Angel Garcia-Bereguiain, PhD

Academic Editor

PLOS Global Public Health

***********************************************************

Reviewer Comments (if any, and for reference):


Articles from PLOS Global Public Health are provided here courtesy of PLOS

RESOURCES